Hsun-Hao Chang1,2,3, Chi-Feng Hung3,4, I-Chih Chen1, Po-Ching Wu1, Li-Wei Liu1, Ching-Chang Fang1. 1. Department of Cardiology, Tainan Municipal Hospital (Managed by Show Chwan Medical Care Corporation), Tainan. 2. Department of Chemistry. 3. Graduate Institute of Biomedical and Pharmaceutical Science. 4. School of Medicine, Fu-Jen Catholic University, New Taipei City, Taiwan.
Abstract
BACKGROUND: Treating vessels with a very small reference vessel diameter (RVD) in coronary artery disease is challenging. OBJECTIVE: Long-term evaluation of new-generation drug-eluting stents (DESs) for the treatment of coronary lesions with different RVDs. METHODS: From April 2009 to March 2019, 780 patients who underwent single coronary stenting were divided into ≤ 2.25 (very small), 2.5-3.0 (small), and ≥ 3.5 mm (large) DES groups after 1:2:2 propensity score matching. The primary endpoint was target lesion failure (TLF), and the secondary endpoints were major adverse cardiac events (MACEs) and stent thrombosis (ST). RESULTS: During 3 years after new-generation DES implantation, TLF and MACE rates were significantly lower in the very small DES group. The risk of TLF was significantly lower in the very small DES group compared to the small DES group [very small vs. small: TLF, adjusted hazard ratio (HR) = 0.282, p = 0.040]. The risks of MACEs and all-cause mortality were significantly lower in the very small DES group compared to the small DES group (very small vs. small: MACEs, adjusted HR = 0.215, p = 0.001; all-cause mortality, adjusted HR = 0.181, p = 0.005). The cumulative incidence rates of TLF-free (log-rank test p = 0.001) and MACE-free (log-rank test p < 0.001) survival were significantly different among the groups, and the very small DES group had a high event-free survival rate. No cases of ST occurred in any group. CONCLUSIONS: Our results indicate that the use of new-generation DESs for treating coronary lesions in very small vessels is safe and effective.
BACKGROUND: Treating vessels with a very small reference vessel diameter (RVD) in coronary artery disease is challenging. OBJECTIVE: Long-term evaluation of new-generation drug-eluting stents (DESs) for the treatment of coronary lesions with different RVDs. METHODS: From April 2009 to March 2019, 780 patients who underwent single coronary stenting were divided into ≤ 2.25 (very small), 2.5-3.0 (small), and ≥ 3.5 mm (large) DES groups after 1:2:2 propensity score matching. The primary endpoint was target lesion failure (TLF), and the secondary endpoints were major adverse cardiac events (MACEs) and stent thrombosis (ST). RESULTS: During 3 years after new-generation DES implantation, TLF and MACE rates were significantly lower in the very small DES group. The risk of TLF was significantly lower in the very small DES group compared to the small DES group [very small vs. small: TLF, adjusted hazard ratio (HR) = 0.282, p = 0.040]. The risks of MACEs and all-cause mortality were significantly lower in the very small DES group compared to the small DES group (very small vs. small: MACEs, adjusted HR = 0.215, p = 0.001; all-cause mortality, adjusted HR = 0.181, p = 0.005). The cumulative incidence rates of TLF-free (log-rank test p = 0.001) and MACE-free (log-rank test p < 0.001) survival were significantly different among the groups, and the very small DES group had a high event-free survival rate. No cases of ST occurred in any group. CONCLUSIONS: Our results indicate that the use of new-generation DESs for treating coronary lesions in very small vessels is safe and effective.
Entities:
Keywords:
Major adverse cardiac events; New-generation drug-eluting stent; Stent thrombosis; Target lesion failure; Very small coronary artery disease
Authors: Zbigniew Kalarus; Radosław Lenarczyk; Jacek Kowalczyk; Oskar Kowalski; Mariusz Gasior; Tomasz Was; Tadeusz Zebik; Hubert Krupa; Piotr Chodór; Lech Poloński; Marian Zembala Journal: Am Heart J Date: 2007-02 Impact factor: 4.749
Authors: Martin Unverdorben; Franz X Kleber; Hubertus Heuer; Hans-Reiner Figulla; Christian Vallbracht; Matthias Leschke; Bodo Cremers; Stefan Hardt; Michael Buerke; Hanns Ackermann; Michael Boxberger; Ralf Degenhardt; Bruno Scheller Journal: EuroIntervention Date: 2013-09 Impact factor: 6.534
Authors: Paul S Teirstein; Ian T Meredith; Robert L Feldman; A Charles Rabinowitz; Louis A Cannon; Tommy C Lee; Joseph Dens; Christophe L Dubois; Michael R Mooney; Vincent J Pompili; Shigeru Saito; Dominic J Allocco; Keith D Dawkins; Gregg W Stone Journal: Catheter Cardiovasc Interv Date: 2014-07-04 Impact factor: 2.692
Authors: David R Holmes; Dean J Kereiakes; Scot Garg; Patrick W Serruys; Gregory J Dehmer; Stephen G Ellis; David O Williams; Takeshi Kimura; David J Moliterno Journal: J Am Coll Cardiol Date: 2010-10-19 Impact factor: 24.094
Authors: Liefke C van der Heijden; Marlies M Kok; Peter W Danse; Alexander R Schramm; Marc Hartmann; Marije M Löwik; Gerard C M Linssen; Martin G Stoel; Carine J M Doggen; Clemens von Birgelen Journal: Am Heart J Date: 2016-03-17 Impact factor: 4.749
Authors: Mallory S Lo-Kioeng-Shioe; Andrea L Vavere; Armin Arbab-Zadeh; Joanne D Schuijf; Carlos E Rochitte; Marcus Y Chen; Matthias Rief; Klaus F Kofoed; Melvin E Clouse; Arthur J Scholte; Julie M Miller; Aisha Betoko; Michael J Blaha; Christopher Cox; Jaap W Deckers; Joao A C Lima Journal: J Am Heart Assoc Date: 2019-03-19 Impact factor: 5.501